DOCSLIB.ORG

Photochemotherapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Photochemotherapy Photochemotherapy Policy Number: Original Effective Date: MM.02.015 11/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service: Home; Office I. Description Photochemotherapy utilizing ultraviolet light type A (UVA) therapy is a treatment that involves exposing the patient to a photosynthesizing agent (psoralens) through oral ingestion or through bath water in conjunction with ultraviolet A light (sunlight or artificial light) for photochemotherapy of skin conditions. UVA therapy utilizing psoralens is also known as PUVA therapy. Photochemotherapy utilizing ultraviolet light type B (UVB) therapy is a treatment that involves exposing the patient to ultraviolet light type B or middle-wave ultraviolet light. It is generally used in combination with tar or anthralin. II. Criteria/Guidelines A. Photochemotherapy utilizing UVA therapy is covered (subject to Limitations/Exclusions and Administrative Guidelines) for the following diagnoses: 1. Pinta 2. Cutaneous T-cell lymphoma 3. Chronic Graft versus Host Disease refractory to standard immunosuppressive drug treatment 4. Psoriasis 5. Parapsoriasis 6. Atopic dermatitis 7. Lichen planus 8. Pityriasis rosea B. Bath water PUVA is covered if all of the following are met: 1. Patient has extensive, severe psoriasis 2. Patient had prior inability to tolerate systemic PUVA therapy and other conventional therapies. 3. Patient had no prior treatment involving carcinogenic materials (with the exception of methotrexate) including tar and UVB treatments, radiation therapy, and arsenic therapy. Photochemotherapy 2 C. Photochemotherapy utilizing UVB therapy is covered (subject to Limitations/Exclusions and Administrative Guidelines) for the following diagnoses: 1. Psoriasis 2. Parapsoriasis 3. Atopic dermatitis 4. Mycosis fungoides 5. Lichen planus 6. Pityriasis rosea D. UVB units are covered for home use when a patient with a chronic condition is expected to need the unit for at least six months. The therapy should first be tried in the physician’s office. Units should only be ordered for home use if therapy is tolerated and if the physician believes the patient will be compliant with regular use in the home setting. E. Photochemotherapy (with UVB plus tar or PUVA for patients with severe photoresponsive dermatoses requiring four to eight hours of care under the direct supervision of a physician is covered (subject to Limitations/Exclusions and Administrative Guidelines) under the following conditions: 1. If the therapy uses PUVA, the covered diagnoses are the same as those listed for criteria II.A. 2. If the therapy uses UVB plus tar, the covered diagnoses are the same as those listed for criteria II.C. III. Limitations A. UVA treatments should be medically supervised and are not covered in the home setting. B. Coverage of bath water PUVA is limited to 30 treatments unless improvement is documented. IV. Administrative Guidelines A. Precertification is not required. HMSA reserves the right to perform retrospective review using the above criteria to validate if services rendered met payment determination criteria. Documentation supporting the medical necessity should be legible and maintained in the patient's medical record and made available to HMSA upon request. B. For coverage for bath water PUVA, the medical record must include documentation of all of the following: 1. Prior inability to tolerate systemic PUVA therapy and other conventional therapies. 2. No prior treatment involving carcinogenic materials (with the exception of methotrexate) including tar and UVB treatments, radiation therapy, and arsenic therapy. Photochemotherapy utilizing UVA therapy codes CPT code Description 96912 Photochemotherapy; psoralens and ultraviolet A (PUVA) ICD-9-CM codes Description A67.2 Pinta, late lesions Photochemotherapy 3 L20.81 – L20.89 Other atopic dermatitis L40.0 – L40.9 Other psoriasis L41.1 Parapsoriasis L41.9 Parapsoriasis, unspecified L42 Pityriasis rosea L43.8 Lichen planus L66.1 Lichen planopilaris C84.40 – C84.49 Peripheral T-cell lymphoma D89.811 Chronic graft versus host disease Photochemotherapy utilizing UVB therapy codes CPT code Description 96910 Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B ICD-10-CM codes Description C84.00 – C84.08 Mycosis fungoides L20.81 – L20.89 Other atopic dermatitis L40.0 – L40.9 Other psoriasis L41.8 Parapsoriasis L41.9 Parapsoriasis, unspecified L42 Pityriasis rosea L43.8 Lichen planus L66.1 Lichen planopilaris Home Ultraviolet B Therapy HCPCS codes Description E0691 Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection; treatment area 2 square feet or less (when specified as UVB) E0692 Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection; 4 foot panel (when specified as UVB) E0693 Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection; 6 foot panel (when specified as UVB) Photochemotherapy 4 E0694 Ultraviolet multidirectional light therapy system in 6 foot cabinet, includes bulbs/lamps, timer and eye protection (when specified as UVB) Photochemotherapy utilizing UVB plus tar or PUVA therapy CPT code Description 96913 Photochemotherapy (Goeckerman and/or PUVA) for severe photoresponsive dermatoses requiring at least four to eight hours of care under direct supervision of the physician (includes application of medication and dressings) ICD-10-CM Codes Description A67.2 Late lesions of pinta C84.00 – C84.08 Mycosis fungoides L20.81 – L20.89 Other atopic dermatitis L40.0 – L40.9 Psoriasis L41.0 Pityriasis lichenoides et varioliformis acuta L41.1 Pityriasis lichenoides chronica L41.8 Other parapsoriasis L41.9 Parapsoriasis, unspecified L42 Pityriasis rosea L43.8 Other lichen planus L66.1 Lichen planopilaris C84.40-C84.49 Peripheral T-cell lymphoma D89.811 Chronic graft versus host disease V. Important Reminder The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician. Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii’s Patients’ Bill of Rights and Responsibilities Act (Hawaii Revised Statutes §432E-1.4), generally accepted standards of medical practice and review of medical literature and government approval Photochemotherapy 5 status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA’s determination as to medical necessity in a given case, the physician may request that HMSA reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation. VI. References 1. Almutawa F, Thalib L, Heckman D et al. Efficacy of localized phototherapy and photodynamic therapy for psoriasis: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed. Nov 28, 2013. 12092: [Epub ahead of print]. 2. Almutawa F, Alnomair N, Wang Y et al. Systematic review of UV-based therapy for psoriasis. Am J Clin Dermatol 2013; 14(2):87-109. 3. BCBSA. Medical Policy Reference Manual. Policy #2.01.07 Psoralens with Ultraviolet A (PUVA) for Psoriasis. Archived January 2012. 4. Bansal S, Sahoo B, Garg V. Psoralen-narrowband UVB phototherapy in treatment of vitiligo in comparison to narrowband UVB phototherapy. Photodermatol Photoimmunol Photomed 2013. 5. Calzavara-Pinton PG, Ortel B, Honigsmann H, Zane C, De Panfilis G. “Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis.” Dermatology 1994; 189(3):256-259. 6. Chen X, Yang M, Cheng Y et al. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev 2013; 10:CD009481. 7. Collins P, Rogers S. “Bath water compared with oral delivery of 8-Methoxypsoralen PUVA therapy for chronic plaque psoriasis.” British Journal of Dermatology 1992; 127(4): 392-395. 8. Hannuksela A, Pukkala E, Hannuksela M, Karvonen J. “Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA.” Journal of the American Academy of Dermatology 1996; 35(5 Pt 1): 685-689. 9. Lowe NJ, Weingarten D, Bourget T, Moy LS. “PUVA therapy for psoriasis: comparison of oral and bath water delivery of 8-Methoxypsoralen.” Journal of the American Academy of Dermatology 1996; 14(5 Pt 1): 754-760. 10. Menter A, Korman NJ, Elmets CA, MD, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. Journal of the American Academy of Dermatology. 62:1; 114-135. 11. Medicare Coverage Issues Manual. Section 35-66: Treatment of Psoriasis. 12. Momtaz TK, Fitzpatrick TB. “Modifications of PUVA.” Dermatologic Clinics 1995; 13(4): 867-73. 13. Morison WL. “PUVA combination therapy.” Photodermatology 1985; 2(4): 229-36. 14. National Psoriasis
Load more

Recommended publications
  • Blistering, Papulosquamous, Connective Tissue and Alopecia Kathleen Haycraft, DNP, FNP/PNP-BC, DCNP, FAANP Objectives
    Blistering, Papulosquamous, Connective Tissue and Alopecia Kathleen Haycraft, DNP, FNP/PNP-BC, DCNP, FAANP Objectives • Identify examples of papulosquamous disease and state treatment options • Identify examples of connective tissue disease and state treatment options • Identify examples of blistering diseases and state treatment options • Identify examples of alopecia and state treatment options Papulosquamous Psoriasis • Latin means “itchy plaque”. • In truth it is less itchy than yeast and eczema • Variable • Painful in high friction spots Psoriasis Plaque ©kathleenhaycraft Psoriasis ©kathleen haycraft ©kathleenhaycraft The clue to the vaginal pic ©kathleenhaycraft ©kathleenhaycraft Plantar Psoriasis ©kathleenhaycraft Palmar Psoriasis ©kathleenhaycraft Nivolumab induced Psoriasis ©kathleenhaycraft@yahoo.com Psoriasis and its many forms • Plaque..85% • Scalp • Palmoplantar • Guttate • Inverse • Erythrodermic • Psoriatic arthritis • Psoriatic nails Cause • Affects 2 to 5% of the population • Many mediators including the T cell lymphocyte. • Many chemicals downstream including TNF alpha, PDE, Il 12, 23, 17 as well as a variety of inflammatory cytokines • These chemicals are distributed throughout the body • Imbalance between pro inflammatory and anti-inflammatory chemicals • Can be triggered by strep, HIV, Hepatitis, and a wide variety of infectious organisms Psoriasis causes • Koebner phenomenon after surgery or trauma • Drugs such as beta blockers, lithium, antimalarials • The cytokines result in proliferation of keratinocytes and angiogenesis (resulting in the Auspitz sign) • May be mild to severe and location of scalp, genitalia, face may trump degree of psoriasis (BSA- Comorbidities • Reviewed in the cutaneous manifestations of systemic disease • Range from depression to MI, psoriatic arthritis, malignancy, Dm • Future treatments may be based on how they treat the comorbids • Diagnose with visual or biopsy Treatment • Topical corticosteroids..caution to not over use particularly in high risk areas.
    [Show full text]
  • History of Psoriasis and Parapsoriasis
    History of Psoriasis and Parapsoriasis By Karl Holubar Summary Parapsoriasis is «oï a disease entity. Jt is an auxiliary term introduced in J 902 to group several dermatoses w>itk a/aint similarity to psoriasis. Tlie liistorical development leading to tlie creation o/ t/ie term parapsoriasis is outlined and t/te Itistory o/psoriasis is 6rie/ly reviewed. Semantic and terminological considerations Obviously, para-psoriasis as a term has been created in analogy to psoriasis. We should remember similar neologisms in medical language, e. g. protein and para-protein; typhoid and para-typhoid, thyroid and para-thyroid, phimosis and para-phimosis, eventually, pemphigus and para-pemphigus (the latter in 1955 this term was to be employed instead of pemphigoid but was not accepted by the dermatological world). Literally, para is a Greek preposition, (with the genitive, dative and accusative), meaning: by the side of, next to something, alongside something. In medicine, para is used often as a prefix to another term, which designates a condition somewhat similar to the one under consideration. The same holds for psoriasis and parapsoria- sis. In detail, though, it is a bit more complicated. Parapsoriasis has more than one "/at/ier", three in fact: ideiurick /Iu.spitz f 1835—1886,), Paul Gerson Luna (A850—1929j and Louis Procç fI856—I928J. Auspitz, in 1881, had published a new system of skin diseases the seventh class of which was called epidermidoses, subdivided into liypcrlcfiratose.s, parakeratoses, kerato/y- ses, the characteristics of which were excessive keratinization, abnormal keratinization and insufficent keratinization. When Unna, in 1890®, pub- lished his two reports on what he called parakeratosis variegata, he referred to Auspitz' system and term when coining his own.
    [Show full text]
  • Dermatological Indications of Disease - Part II This Patient on Dialysis Is Showing: A
    “Cutaneous Manifestations of Disease” ACOI - Las Vegas FR Darrow, DO, MACOI Burrell College of Osteopathic Medicine This 56 year old man has a history of headaches, jaw claudication and recent onset of blindness in his left eye. Sed rate is 110. He has: A. Ergot poisoning. B. Cholesterol emboli. C. Temporal arteritis. D. Scleroderma. E. Mucormycosis. Varicella associated. GCA complex = Cranial arteritis; Aortic arch syndrome; Fever/wasting syndrome (FUO); Polymyalgia rheumatica. This patient missed his vaccine due at age: A. 45 B. 50 C. 55 D. 60 E. 65 He must see a (an): A. neurologist. B. opthalmologist. C. cardiologist. D. gastroenterologist. E. surgeon. Medscape This 60 y/o male patient would most likely have which of the following as a pathogen? A. Pseudomonas B. Group B streptococcus* C. Listeria D. Pneumococcus E. Staphylococcus epidermidis This skin condition, erysipelas, may rarely lead to septicemia, thrombophlebitis, septic arthritis, osteomyelitis, and endocarditis. Involves the lymphatics with scarring and chronic lymphedema. *more likely pyogenes/beta hemolytic Streptococcus This patient is susceptible to: A. psoriasis. B. rheumatic fever. C. vasculitis. D. Celiac disease E. membranoproliferative glomerulonephritis. Also susceptible to PSGN and scarlet fever and reactive arthritis. Culture if MRSA suspected. This patient has antithyroid antibodies. This is: • A. alopecia areata. • B. psoriasis. • C. tinea. • D. lichen planus. • E. syphilis. Search for Hashimoto’s or Addison’s or other B8, Q2, Q3, DRB1, DR3, DR4, DR8 diseases. This patient who works in the electronics industry presents with paresthesias, abdominal pain, fingernail changes, and the below findings. He may well have poisoning from : A. lead. B.
    [Show full text]
  • Differential Diagnosis in Dermatology
    Differential Diagnosis in Dermatology ZohrehTehranchi Dermatologist COMMON ACNE AND CYSTIC ACNE Rosacea Rosacea PERIORAL DERMATITIS ECZEMA/DERMATITIS Chronic irritant dermatitis Dyshidrotic eczematous dermatitis Childood atopic dermatitis Autosensitization dermatitis (“id” reaction): dermatophytid Seborrheic dermatitis PSORIASIS VULGARIS Pemphigus vulgaris BULLOUS PEMPHIGOID (BP) Pityriasis rosea small-plaque parapsoriasis Large-plaque parapsoriasis (parapsoriasis en plaques) LICHEN PLANUS (LP) GRANULOMA ANNULARE (GA) Erythema multiforme ERYTHEMA NODOSUM Actinic keratoses Bowen disease (Squamous cell carcinoma in situ) Bowen disease and invasive SCC Squamous cell carcinoma: invasive on the lip Squamous cell carcinoma, well differentiated Squamous cell carcinoma, undifferentiated Squamous cell carcinoma, advanced, well differentiated, on the hand Keratoacanthoma showing different stages of evolution BASAL CELL CARCINOMA (BCC) Basal cell carcinoma, ulcerated: Rodent ulcer A large rodent ulcer in the nuchal and Bas cell calarcinoma: sclerosing type retroauricular area extending to the temple Basal cell carcinoma, sclerosing, nodular, Superficial basal cell carcinoma: solitary lesion and multiple lesions Superficial basal cell carcinoma, invasive Basal cell carcinoma, pigmented Dysplastic nevi Superficial spreading melanoma: arising within a dysplastic nevus Congenital nevomelanocytic nevus Melanoma: arising in small CNMN Melanoma in situ: lentigo maligna Melanoma in situ, superficial spreading type Superficial spreading melanoma, vertical
    [Show full text]
  • Papular Pityriasis Rosea
    Continuing Medical Education Papular Pityriasis Rosea 2nd Lt Ronald M. Bernardin, MSC, USAF; Maj Steven E. Ritter, MC, FS, USAF; Lt Col Michael R. Murchland, MC, FS, USAF GOAL To describe a case of papular pityriasis rosea (PR) OBJECTIVES Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Outline the varying clinical presentations of PR. 2. Discuss the theoretical etiologies of PR. 3. Describe therapy for PR. CME Test on page 48. This article has been peer reviewed and Medicine is accredited by the ACCME to provide approved by Michael Fisher, MD, Professor of continuing medical education for physicians. Medicine, Albert Einstein College of Medicine. Albert Einstein College of Medicine designates Review date: June 2002. this educational activity for a maximum of 1.0 hour This activity has been planned and implemented in category 1 credit toward the AMA Physician’s in accordance with the Essential Areas and Policies Recognition Award. Each physician should claim of the Accreditation Council for Continuing Medical only those hours of credit that he/she actually spent Education through the joint sponsorship of Albert in the educational activity. Einstein College of Medicine and Quadrant This activity has been planned and produced in HealthCom, Inc. The Albert Einstein College of accordance with ACCME Essentials. Pityriasis rosea (PR) is a seasonal papulosqua- and treatment options. Papular PR is atypical, pre- mous disorder that can be easily confused with a senting in a minority of patients, and may pose a wide variety of similar appearing cutaneous disor- diagnostic challenge. Being familiar with these ders.
    [Show full text]
  • Pediatric Psoriasis
    Pediatric Papulosquamous and Eczematous Disorders St. John’s Episcopal Hospital Program Director- Dr. Suzanne Sirota-Rozenberg Dr. Brett Dolgin, DO Dr. Asma Ahmed, DO Dr. Anna Slobodskya, DO Dr. Stephanie Lasky, DO Dr. Louis Siegel, DO Dr. Evelyn Gordon, DO Dr. Vanita Chand, DO Pediatric Psoriasis Epidemiology • Psoriasis can first appear at any age, from infancy to the eighth decade of life • The prevalence of psoriasis in children ages 0 to 18 years old is 1% with an incidence of 40.8 per 100,000 ppl • ~ 75% have onset before 40 years of age What causes psoriasis? • Multifactorial • Genetics – HLA associations (Cw6, B13, B17, B57, B27, DR7) • Abnormal T cell activation – Th1, Th17 with increased cytokines IL 1, 2, 12, 17, 23, IFN-gamma, TNF-alpha • External triggers: – Injury (Koebner phenomenon) – medications (lithium, IFNs, β-blockers, antimalarials, rapid taper of systemic corticosteroids) – infections (particularly streptococcal tonsillitis). Pediatric Psoriasis Types: • Acute Guttate Psoriasis – Small erythematous plaques occurring after infection (MOST common in children) • 40% of patients with guttate psoriasis will progress to develop plaque type psoriasis • Chronic plaque Psoriasis – erythematous plaques with scaling • Flexural Psoriasis – Erythematous areas between skin folds • Scalp Psoriasis – Thick scale found on scalp • Nail Psoriasis – Nail dystrophy • Erythrodermic Psoriasis– Severe erythema covering all or most of the body • Pustular Psoriasis – Acutely arising pustules • Photosensitive Psoriasis – Seen in areas of sun
    [Show full text]
  • Buffalo Medical Group, P.C. Robert E
    Buffalo Medical Group, P.C. Robert E. Kalb, M.D. Phone: (716) 630-1102 Fax: (716) 633-6507 Department of Dermatology 325 Essjay Road Williamsville, New York 14221 2 FOOT- 1 HAND SYNDROME 2 foot - 1 hand syndrome is a superficial infection of the skin caused by the common athlete's foot fungus. It is quite common for people to have a minor amount of an athlete's foot condition. This would appear as slight scaling and/or itching between the toes. In addition, patients may have thickened toenails as part of the athlete's foot condition. Again the problem on the feet is very common and often patients are not even aware of it. In some patients, however, the athlete's foot fungus can spread to another area of the body. For some strange and unknown reason, it seems to affect only one hand. That is why the condition is called 2 foot - 1 hand syndrome. It is not clear why the problem develops in only one hand or why the right or left is involved in some patients. Fortunately there is very effective treatment to control this minor skin problem. If the problem with the superficial fungus infection is confined to the skin, then a short course of treatment with an oral antibiotic is all that is required. This antibiotic is very safe and normally clears the skin up fairly rapidly. It is often used with a topical cream to speed the healing process. If, however, the fingernails of the affected hand are also involved then a more prolonged course of the antibiotic will be necessary.
    [Show full text]
  • Home Phototherapy Order Form
    Physician’s Written Order for Home Phototherapy Fax to: 605-322-2475 or Email: MCK-MBX-HMEAccessServices@Avera.org This form is a Prescription and Statement of Medical Necessity for Daavlin home phototherapy products Rx used for the treatment of skin conditions such as psoriasis. All fields required for insurance approval. First Name _______________________ Last Name _________________________ DOB ____/____/____ Gender: M F Address _____________________________________________ City_________________________ State_____ Zip__________ Patient Info: Patient Phone #________________________________ Alt Phone # or Email _______________________________________________ HCPCs: Product and Description: Physician Name ___________________________________ DermaPal: Hand-held treatment wand for scalp, Practice __________________________________________ E0691 spot treatment or travel. Includes comb attachment. NPI# ______________________________________________ E0691 1 Series: Small, light-weight panel for hands, face, Address _________________________________________ feet, elbows, or any other localized treatment area. City ______________________ State ____ Zip _________ 7 Series 8 Lamp: Six foot tall, multi-directional unit Info: Physician Prescribing Phone (____)______________*Fax (____)______________ Home Phototherapy Product: Home Phototherapy E0694 for large areas and/or full body treatment. * IMPORTANT: We will use this fax number to fax the Prescriber’s Dosing Guide ICD-10 Code: Description: ICD-10 Code Estimated Duration of Need: ___ Months (
    [Show full text]
  • A Retrospective Study of the Probability of the Evolution of Parapsoriasis En Plaques Into Mycosis Fungoides
    Acta Derm Venereol 2005; 85: 318–323 INVESTIGATIVE REPORT A Retrospective Study of the Probability of the Evolution of Parapsoriasis en Plaques into Mycosis Fungoides Liisa VA¨ KEVA¨ 1, Seppo SARNA3, Annikki VAALASTI4, Eero PUKKALA5, Arja-Leena KARINIEMI2 and Annamari RANKI1 Departments of 1Dermatology and Venereal Diseases and 2Pathology, Skin and Allergy Hospital, Helsinki University Hospital, 3Department of Public Health, University of Helsinki, Helsinki, 4Department of Dermatology, Tampere University Hospital, Tampere and 5Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland Parapsoriasis en plaque has been suggested to be an early with parapsoriasis en plaque in fact represent early manifestation of mycosis fungoides (cutaneous T-cell MF (5, 6). lymphoma). We explored the disease course of patients According to current dermatology textbooks, para- with small plaque or large plaque parapsoriasis in a 26- psoriasis en plaques is divided into two clinically year retrospective cohort analysis of 105 parapsoriasis different entities: small plaque parapsoriasis (SPP) and patients, who were clinically and histopathologically large plaque parapsoriasis (LPP). LPP in particular is followed up in Helsinki and Tampere University often clinically indistinguishable from MF (7, 8). The Hospitals. Eventual later cancers of these patients were differential diagnosis of SPP and LPP is usually based verified from the Finnish Cancer Registry. In the small both on clinical and histopathological findings, because plaque parapsoriasis group, 7 patients (10%) and in the both diseases have superficial lymphocyte inflammation large plaque parapsoriasis group 12 patients (35%), with various degree of epidermotropism. The diagnosis developed histologically confirmed mycosis fungoides of MF is based on the atypical features of infiltrating during a median of 10 and 6 years, respectively.
    [Show full text]
  • Treatment for Skin Conditions Page 1 of 17
    Version 2.0 Johns Hopkins HealthCare LLC Policy Number CMS16.02 Medical Policy Effective Date 08/02/2021 Medical Policy Review Date 05/18/2021 Subject Revision Date 05/18/2021 Treatment for Skin Conditions Page 1 of 17 This document applies to the following Participating Organizations: EHP Johns Hopkins Advantage MD Priority Partners US Family Health Plan Keywords: Laser treatment, Phototherapy, Psoralens and ultraviolet A (PUVA), Skin conditions Table of Contents Page Number I. ACTION 1 II. POLICY DISCLAIMER 1 III. POLICY 1 IV. POLICY CRITERIA 2 V. DEFINITIONS 6 VI. BACKGROUND 7 VII. CODING DISCLAIMER 8 VIII. CODING INFORMATION 9 IX. REFERENCES 13 X. REFERENCE STATEMENT 17 XI. APPROVALS 17 I. ACTION New Policy X Revising Policy Number CMS16.02 & CMS01.04 Superseding Policy Number Archiving Policy Number Retiring Policy Number II. POLICY DISCLAIMER Johns Hopkins HealthCare LLC (JHHC) provides a full spectrum of health care products and services for Employer Health Programs, Priority Partners, Advantage MD and US Family Health Plan. Each line of business possesses its own unique contract and guidelines which, for benefit and payment purposes, should be consulted first to know what benefits are available for coverage. Specific contract benefits, guidelines or policies supersede the information outlined in this policy. III. POLICY For Advantage MD refer to: Medicare Coverage Database • Local Coverage Determination (LCD) L34938 Removal of Benign Skin Lesions • Local Coverage Article: Billing and Coding: A57113 Removal of Benign Skin Lesions
    [Show full text]
  • 059 BCBSA Reference Number: 2.01.47; 2.01.86
    Medical Policy Phototherapy: PUVA, UV-B and Targeted Phototherapy Table of Contents • Policy: Commercial • Coding Information • Information Pertaining to All Policies • Policy: Medicare • Description • References • Authorization Information • Policy History • Endnotes Policy Number: 059 BCBSA Reference Number: 2.01.47; 2.01.86 Related Policies Dermatologic Applications of Photodynamic Therapy, #463 Policy Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members Photochemotherapy with psoralen plus ultraviolet A (PUVA) - OFFICE SETTING PUVA treatment for the following conditions may be considered MEDICALLY NECESSARY: • Parapsoriasis • Atopic dermatitis/ Eczema • Lichen planus • Urticaria pigmentosa • Chronic recalcitrant dermatitis • Pruritus • Dyshidrosis • pityriasis lichenoides chronica • Alopecia areata (if conservative treatment has failed) • Vitiligo. PUVA for the treatment of severe, disabling psoriasis, which is not responsive to other forms of conservative therapy (eg, topical corticosteroids, coal/tar preparations, and ultraviolet light), may be considered MEDICALLY NECESSARY.5 PUVA treatment as initial (primary) treatment for mycosis fungoides stage I (early infiltrative) and stage II (infiltrative plaques) may be considered MEDICALLY NECESSARY. PUVA treatment is INVESTIGATIONAL for other conditions not listed above. 1 Relative Contraindications to PUVA Therapy1 The following are relative contraindications to PUVA therapy. Coverage is determined at the physician’s
    [Show full text]
  • Clinical Pattern of Papulosquamous Dermatoses: an Observational Study Conducted at Tertiary Care Center, Ujjain, Madhya Pradesh, India
    International Journal of Research in Dermatology Varma K et al. Int J Res Dermatol. 2020 Mar;6(2):230-236 http://www.ijord.com DOI: http://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20200602 Original Research Article Clinical pattern of papulosquamous dermatoses: an observational study conducted at tertiary care center, Ujjain, Madhya Pradesh, India Krishnendra Varma, Ujjwal Kumar, Varun Kumar* Department of Dermatology, Venereology and Leprology, R.D Gardi Medical College, Ujjain, Madhya Pradesh, India Received: 11 November 2019 Accepted: 10 January 2020 *Correspondence: Dr. Varun Kumar, E-mail: varunkumarshobha@gmail.com Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Papulosquamous dermatoses is a complex group of disorder characterized by scaly papules and plaques. There is a need to study the exact, pattern and prevalence of this disorder in different age groups and their line of treatment. Objective of the study was to observe the clinical pattern of various papulosquamous dermatoses and their prevalence at tertiary care center, Ujjain. Methods: This was an observational study done in R.D. Gardi Medical college, Ujjain over a period of one year. A total of 229 cases including male and female of papulosquamous dermatoses were enrolled from the outpatient department. All patients were studied clinically and relevant data was recorded. Microsoft excel was used for data entry and analysis was done using SPSS version 23.
    [Show full text]